BioSpace News Archive

SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2018. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov’ 2018 at Hyderabad.

Investigating a new marker for chronic inflammation GlycA, researchers have found that chronic inflammation is linked to increased risk for shorter lifespan and several organ-related diseases. The findings were made through investigating GlycA measurements with Nightingale Health’s blood testing technology. The results highlight a potential use for measuring GlycA in healthcare.

DCCR treatment resulted in statistically significant decreases in body fat in subjects with Prader-Willi Syndrome

The conference will bring international experts to the region who will give insights on breakthroughs in fertility treatments

New Regenstrief and IU methodology identifies, swiftly implements evidence-based solutions

How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomised trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo.

Immunicum AB announced today that it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate its lead product, ilixadencel, an off-the-shelf cell-based cancer immune primer, in combination with avelumab*, a human anti-PD-L1 monoclonal antibody, in a planned multi-indication Phase Ib/II clinical trial.

Overall response rate at 28 days of 60%, complete response rate of 50%

Vectura was studying VR475, a drug-device combination consisting of budesonide delivered by Vectura’s proprietary nebulizer inhalation system as a treatment for adolescent and adult patients with severe uncontrolled asthma.

Bristol-Myers Squibb and LabCentral, a Cambridge, Mass.-based shared laboratory space, announced the two winners of the Bristol-Myers Squibb’s 2018 Golden Tickets for LabCentral. Due to being a platinum sponsor, Bristol-Myers Squibb could choose up to two innovative life science companies per year for Golden Tickets. This covers the cost of one lab bench for one year at LabCentral’s facility at Kendall Square in Cambridge.